<DOC>
	<DOCNO>NCT00947349</DOCNO>
	<brief_summary>The current Standard Care ( SOC ) chronic HCV infection , pegylated interferon-alfa combination therapy ribavirin 24-48 week treatment , effective part patient often associate severe adverse effect lead discontinuation treatment dose modification . A number compound direct activity currently clinical development , incl . BI 201335 . BI 201335 work prevent Hepatitis C virus replicate bind HCV protease ( enzyme ) . The main purpose clinical trial BI 201335 see well BI 201335 work safe BI 201335 use daily combination PegIFN RBV HCV infect patient</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Rising Oral Doses BI 201335 Softgel Capsule Naive Hepatitis C Virus ( HCV ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Inclusion criterion : chronic HCV genotype1 ; high viral load Exclusion criterion : Mixed genotype ( 1/2 , 1/3 , 1/4 ) , diagnose genotypic test screen Previous treatment protease inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>